Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis

Overview of attention for article published in Frontiers in oncology, September 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 14 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 25,161 followers.

Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis: Background, Pembrolizumab and cemiplimab… #oncology https://t.co/Pm

27 Sep 2022

Reply Repost Favourite

New research: Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis: Background Pembrolizumab and cemiplimab… https://t.co

26 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.